| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 267.844 | 262.738 | 292.748 | 357.596 | 359.243 | 330.908 | 282.139 | 421.576 | 336.377 | 475.529 |
| Total Income - EUR | 272.214 | 262.747 | 295.992 | 357.604 | 359.252 | 332.598 | 282.149 | 422.090 | 336.558 | 490.287 |
| Total Expenses - EUR | 234.922 | 193.003 | 230.706 | 302.109 | 256.698 | 231.301 | 206.451 | 307.046 | 273.559 | 321.673 |
| Gross Profit/Loss - EUR | 37.292 | 69.744 | 65.286 | 55.494 | 102.554 | 101.296 | 75.699 | 115.044 | 62.998 | 168.614 |
| Net Profit/Loss - EUR | 37.292 | 69.744 | 62.497 | 51.918 | 99.172 | 98.136 | 72.934 | 111.203 | 60.232 | 154.931 |
| Employees | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Check the financial reports for the company - Silvucutac S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 6.710 | 5.032 | 20.160 | 18.631 | 12.898 | 19.146 | 16.255 | 10.186 | 5.220 | 9.366 |
| Current Assets | 95.731 | 117.767 | 142.148 | 182.385 | 197.495 | 203.602 | 159.040 | 182.757 | 184.392 | 176.655 |
| Inventories | 13.853 | 24.459 | 32.012 | 79.272 | 59.915 | 49.336 | 33.109 | 32.071 | 117.817 | 35.755 |
| Receivables | 26.569 | 34.498 | 49.051 | 47.303 | 64.824 | 99.695 | 47.416 | 107.955 | 28.628 | 58.968 |
| Cash | 55.309 | 58.810 | 61.085 | 55.810 | 72.757 | 54.571 | 78.515 | 42.731 | 37.948 | 81.932 |
| Shareholders Funds | -84.652 | -14.044 | 48.690 | 99.715 | 196.957 | 204.312 | 134.401 | 111.251 | 94.217 | 155.140 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 187.092 | 136.843 | 113.618 | 101.301 | 13.437 | 18.435 | 40.185 | 81.692 | 95.396 | 30.880 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 708 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4671 - 4671" | |||||||||
| CAEN Financial Year |
4671
|
|||||||||
Comments - Silvucutac S.r.l.